Cargando…

Development of a Stability-Indicating RP-HPLC Method for the Determination of Rupatadine and its Degradation Products in Solid Oral Dosage Form

A simple, sensitive, and reproducible reversed-phase high-performance liquid chromatography (RP-HPLC) method, coupled with a photodiode array detector, was developed for the determination of rupatadine (RUPA) and its related substances in pharmaceutical dosage forms. Chromatographic separation was a...

Descripción completa

Detalles Bibliográficos
Autores principales: Trivedi, Harshal Kanubhai, Patel, Mukesh C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Österreichische Apotheker-Verlagsgesellschaft 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3528052/
https://www.ncbi.nlm.nih.gov/pubmed/23264938
http://dx.doi.org/10.3797/scipharm.1208-10
_version_ 1782253787051720704
author Trivedi, Harshal Kanubhai
Patel, Mukesh C.
author_facet Trivedi, Harshal Kanubhai
Patel, Mukesh C.
author_sort Trivedi, Harshal Kanubhai
collection PubMed
description A simple, sensitive, and reproducible reversed-phase high-performance liquid chromatography (RP-HPLC) method, coupled with a photodiode array detector, was developed for the determination of rupatadine (RUPA) and its related substances in pharmaceutical dosage forms. Chromatographic separation was achieved on the Hypersil BDS (150 x 4.6 mm, 5 μm) column with a mobile phase containing a gradient mixture of a buffer (acetate buffer pH-6.0) and solvent (methanol). The eluted compounds were monitored at 264 nm for the related substances and assay, the flow rate was 1.0 mL/min, and the column oven temperature was maintained at 50°C. The developed method separated RUPA from its four known and three unknown impurities within 15.0 min. Rupatadine was subjected to the stress conditions of oxidative, acid, base, hydrolytic, thermal, and photolytic degradation. Rupatadine was found to degrade significantly under oxidative stress conditions, and degrade slightly under acid, base, hydrolytic, thermal, and photolytic stress conditions. All impurities were well-resolved from each other and from the main peak, showing the stability-indicating power of the method. The developed method was validated as per the International Conference on Harmonization (ICH) guidelines. The developed and validated RP-HPLC method is LC-MS compatible and can be explored for the identification of eluted unknown impurities of RUPA.
format Online
Article
Text
id pubmed-3528052
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Österreichische Apotheker-Verlagsgesellschaft
record_format MEDLINE/PubMed
spelling pubmed-35280522012-12-21 Development of a Stability-Indicating RP-HPLC Method for the Determination of Rupatadine and its Degradation Products in Solid Oral Dosage Form Trivedi, Harshal Kanubhai Patel, Mukesh C. Sci Pharm Research Article A simple, sensitive, and reproducible reversed-phase high-performance liquid chromatography (RP-HPLC) method, coupled with a photodiode array detector, was developed for the determination of rupatadine (RUPA) and its related substances in pharmaceutical dosage forms. Chromatographic separation was achieved on the Hypersil BDS (150 x 4.6 mm, 5 μm) column with a mobile phase containing a gradient mixture of a buffer (acetate buffer pH-6.0) and solvent (methanol). The eluted compounds were monitored at 264 nm for the related substances and assay, the flow rate was 1.0 mL/min, and the column oven temperature was maintained at 50°C. The developed method separated RUPA from its four known and three unknown impurities within 15.0 min. Rupatadine was subjected to the stress conditions of oxidative, acid, base, hydrolytic, thermal, and photolytic degradation. Rupatadine was found to degrade significantly under oxidative stress conditions, and degrade slightly under acid, base, hydrolytic, thermal, and photolytic stress conditions. All impurities were well-resolved from each other and from the main peak, showing the stability-indicating power of the method. The developed method was validated as per the International Conference on Harmonization (ICH) guidelines. The developed and validated RP-HPLC method is LC-MS compatible and can be explored for the identification of eluted unknown impurities of RUPA. Österreichische Apotheker-Verlagsgesellschaft 2012 2012-10-01 /pmc/articles/PMC3528052/ /pubmed/23264938 http://dx.doi.org/10.3797/scipharm.1208-10 Text en © Trivedi and Patel; licensee Österreichische Apotheker-Verlagsgesellschaft m. b. H., Vienna, Austria. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Trivedi, Harshal Kanubhai
Patel, Mukesh C.
Development of a Stability-Indicating RP-HPLC Method for the Determination of Rupatadine and its Degradation Products in Solid Oral Dosage Form
title Development of a Stability-Indicating RP-HPLC Method for the Determination of Rupatadine and its Degradation Products in Solid Oral Dosage Form
title_full Development of a Stability-Indicating RP-HPLC Method for the Determination of Rupatadine and its Degradation Products in Solid Oral Dosage Form
title_fullStr Development of a Stability-Indicating RP-HPLC Method for the Determination of Rupatadine and its Degradation Products in Solid Oral Dosage Form
title_full_unstemmed Development of a Stability-Indicating RP-HPLC Method for the Determination of Rupatadine and its Degradation Products in Solid Oral Dosage Form
title_short Development of a Stability-Indicating RP-HPLC Method for the Determination of Rupatadine and its Degradation Products in Solid Oral Dosage Form
title_sort development of a stability-indicating rp-hplc method for the determination of rupatadine and its degradation products in solid oral dosage form
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3528052/
https://www.ncbi.nlm.nih.gov/pubmed/23264938
http://dx.doi.org/10.3797/scipharm.1208-10
work_keys_str_mv AT trivediharshalkanubhai developmentofastabilityindicatingrphplcmethodforthedeterminationofrupatadineanditsdegradationproductsinsolidoraldosageform
AT patelmukeshc developmentofastabilityindicatingrphplcmethodforthedeterminationofrupatadineanditsdegradationproductsinsolidoraldosageform